Latest From Hitachi Ltd.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
Turkey’s health ministry has disclosed that the forthcoming $10bn medical device tender must come with conditions that strengthen the local manufacturing infrastructure. It must also give Turkey “real” technology with IP rights, not merely an assembly activity for parts manufactured abroad. The tender will be ready in some two to three months.
Big – or more accurately “complex” – data are being used by Japan’s Hitachi Ltd. in programs to re-engineer health care delivery systems. But a real and lasting shift can only happen with a combination of “digitalization” and getting people to change, Hitachi Consulting tells IN VIVO.
Toshiba Medical Systems is among the global imaging industry’s top three companies by sales. But it lays claim to first place in certain technology subsectors and in the innovative ways it helps providers address patient demand.
- Medical Devices
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Hitachi Ltd.
- Senior Management
- Katsushige Mita, Pres. & CEO
- Contact Info
Phone: (81) 32581111
4-6 Kanda-Surugadai, Chiyoda-ku
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.